Balyasny Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-364,068
| Closed | -$4.5M | – | 3311 |
|
|
2022
Q4 | $4.5M | Buy |
364,068
+336,332
| +1,213% | +$4.76M | 0.01% | 1075 |
|
|
2022
Q3 | $387K | Buy |
27,736
+17,356
| +167% | +$279K | ﹤0.01% | 2108 |
|
|
2022
Q2 | $143K | Buy |
+10,380
| New | +$166K | ﹤0.01% | 2241 |
|
|
2022
Q1 | – | Sell |
-19,333
| Closed | -$315K | – | 2975 |
|
|
2021
Q4 | $315K | Sell |
19,333
-221,398
| -92% | -$3.73M | ﹤0.01% | 1731 |
|
|
2021
Q3 | $3.58M | Buy |
+240,731
| New | +$3.85M | 0.01% | 937 |
|
|
2020
Q2 | – | Sell |
-5,439
| Closed | -$342K | – | 1578 |
|
|
2020
Q1 | $342K | Sell |
5,439
-55,156
| -91% | -$4.96M | ﹤0.01% | 967 |
|
|
2019
Q4 | $7.51M | Buy |
+60,595
| New | +$5.42M | 0.04% | 497 |
|
|
2018
Q4 | – | Sell |
-22,000
| Closed | -$2.78M | – | 1852 |
|
|
2018
Q3 | $2.78M | Sell |
22,000
-23,534
| -52% | -$2.49M | 0.01% | 890 |
|
|
2018
Q2 | $3.82M | Buy |
+45,534
| New | +$3.33M | 0.02% | 737 |
|
|
2018
Q1 | – | Sell |
-50,716
| Closed | -$2.96M | – | 2414 |
|
|
2017
Q4 | $2.96M | Sell |
50,716
-90,684
| -64% | -$5.72M | 0.01% | 1026 |
|
|
2017
Q3 | $8.21M | Buy |
141,400
+27,696
| +24% | +$2.98M | 0.03% | 571 |
|
|
2017
Q2 | $13.8M | Buy |
+113,704
| New | +$13.2M | 0.06% | 432 |
|
|
2017
Q1 | – | Sell |
-21,227
| Closed | -$2.31M | – | 1837 |
|
|
2016
Q4 | $2.31M | Buy |
21,227
+7,025
| +49% | +$837K | 0.01% | 859 |
|
|
2016
Q3 | $2.34M | Buy |
+14,202
| New | +$2.24M | 0.01% | 596 |
|
Balyasny Asset Management's ICPT Position: Q1 2023 in Review
Balyasny Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 364,068 shares — an estimated $4.5M sold.
Balyasny Asset Management first reported a position in ICPT in Q3 2016 and held it in 14 quarters. The position peaked at $13.8M in Q2 2017. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.
- Balyasny Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Balyasny Asset Management sold 364,068 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.5M.
- Balyasny Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and held it in 14 quarters.
- Balyasny Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $13.8M in Q2 2017.
- 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.
Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.